Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Lennox-Gastaut Syndrome Overview | 6 | 1 |
| Therapeutics Development | 7 | 2 |
| Pipeline Products for Lennox-Gastaut Syndrome Overview | 7 | 1 |
| Pipeline Products for Lennox-Gastaut Syndrome Comparative Analysis | 8 | 1 |
| Lennox-Gastaut Syndrome Therapeutics under Development by Companies | 9 | 2 |
| Lennox-Gastaut Syndrome Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Lennox-Gastaut Syndrome Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Lennox-Gastaut Syndrome Products under Development by Companies | 15 | 1 |
| Lennox-Gastaut Syndrome Products under Investigation by Universities/Institutes | 16 | 1 |
| Lennox-Gastaut Syndrome Companies Involved in Therapeutics Development | 17 | 3 |
| Eisai Co., Ltd. | 17 | 1 |
| GW Pharmaceuticals Plc | 18 | 1 |
| INSYS Therapeutics, Inc. | 19 | 1 |
| Lennox-Gastaut Syndrome Therapeutics Assessment | 20 | 8 |
| Assessment by Monotherapy Products | 20 | 1 |
| Assessment by Target | 21 | 2 |
| Assessment by Mechanism of Action | 23 | 2 |
| Assessment by Route of Administration | 25 | 1 |
| Assessment by Molecule Type | 26 | 2 |
| Drug Profiles | 28 | 11 |
| cannabidiol - Drug Profile | 28 | 1 |
| Product Description | 28 | 1 |
| Mechanism of Action | 28 | 1 |
| R&D Progress | 28 | 3 |
| cannabidiol - Drug Profile | 31 | 1 |
| Product Description | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| R&D Progress | 31 | 2 |
| NRP-2945 - Drug Profile | 33 | 1 |
| Product Description | 33 | 1 |
| Mechanism of Action | 33 | 1 |
| R&D Progress | 33 | 2 |
| perampanel - Drug Profile | 35 | 1 |
| Product Description | 35 | 1 |
| Mechanism of Action | 35 | 1 |
| R&D Progress | 35 | 3 |
| Small Molecules to Inhibit Voltage Gated Sodium Channels for Lennox Gastaut Syndrome - Drug Profile | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 1 |
| Lennox-Gastaut Syndrome Recent Pipeline Updates | 39 | 12 |
| Lennox-Gastaut Syndrome Product Development Milestones | 51 | 8 |
| Featured News &Press Releases | 51 | 1 |
| Feb 25, 2016: Edison Issues ADR Update on GW Pharmaceuticals | 51 | 1 |
| Dec 07, 2015: GW Pharmaceuticals Announces New Physician Reports of Epidiolex Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy | 51 | 3 |
| Jun 11, 2015: GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study of Epidiolex in Lennox-Gastaut Syndrome | 54 | 1 |
| May 11, 2015: GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex (CBD) in Lennox-Gastaut Syndrome | 54 | 1 |
| Apr 23, 2015: Insys Therapeutics Commences Dosing in Phase 1/2 Safety and Pharmacokinetic Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients | 55 | 1 |
| Jan 12, 2015: Insys Therapeutics To Initiate Phase III study For An Epileptic Drug | 56 | 1 |
| Dec 05, 2014: Eisai Presents New Data on Rufinamide at the 68th Annual American Epilepsy Society Meeting | 56 | 1 |
| Oct 15, 2014: U.S. FDA Accepts Eisai's sNDA for BANZEL (Rufinamide) as Adjunctive Treatment in Pediatric Patients With Lennox-Gastaut Syndrome | 57 | 1 |
| Jun 25, 2014: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Rare Form of Epilepsy, Lennox-Gastaut Syndrome | 57 | 1 |
| May 07, 2014: GW Pharmaceuticals Receives Investigational New Drug From FDA for Phase 2/3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome | 58 | 1 |
| Appendix | 59 | 2 |
| Methodology | 59 | 1 |
| Coverage | 59 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |